ViralGuard
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $300M
Overview
Developing novel, rapidly adaptable vaccine platforms for infectious diseases and pandemic preparedness.
Infectious Disease
Technology Platform
A next-generation vaccine platform designed for rapid development, broad protection, and improved stability against evolving viral pathogens.
Funding History
1Total raised:$300M
Series A$300M
Opportunities
Significant opportunity for government and global health partnerships, especially if its platform proves adaptable against a future pandemic threat.
Risk Factors
Platform may fail to demonstrate superior immunogenicity or efficacy compared to existing, validated vaccine technologies in clinical trials.
Competitive Landscape
Competes in the innovative vaccine space against large, established players (e.g., Moderna, Pfizer) and other platform biotechs, with high technical and regulatory hurdles.